References of "Annals of the Rheumatic Diseases"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAdalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
Burmester, G. R.; Mariette, X.; Montecucco, C. et al

in Annals of the Rheumatic Diseases (2007), 66(6), 732-739

Objective: To evaluate the safety and effectiveness of adalimumab alone or in combination with standard disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA ... [more ▼]

Objective: To evaluate the safety and effectiveness of adalimumab alone or in combination with standard disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA). Methods: Patients with active RA despite treatment with DMARDs or prior treatment with a tumour necrosis factor antagonist participated in a multicentre, open-label clinical study of adalimumab 40 mg every other week for 12 weeks with an optional extension phase. Patients were allowed to continue with pre-existing traditional DMARDs. Long- term safety results are reported for all patients (4210 patient-years (PYs) of adalimumab exposure). The observed effectiveness results at week 12 are reported using American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) response criteria. Results: Among the 6610 treated patients, adalimumab was generally well tolerated. Serious infections occurred in 3.1% of patients (5.5/100 PYs, including active tuberculosis, 0.5/100 PYs). Demyelinating disease (0.06%) and systemic lupus erythematosus (0.03%) were rare serious adverse events. The standardised incidence ratio of malignancy was 0.71 (95% CI 0.49 to 1.01). The standardised mortality ratio was 1.07 ( 95% CI 0.75 to 1.49). At week 12, 69% of patients achieved an ACR20 response, 83% a moderate, and 33% a good EULAR response. Adalimumab was effective in combination with a variety of DMARDs. The addition of adalimumab to antimalarials was comparably effective to the combination of adalimumab and methotrexate. Conclusions: Considering the limitations of an open- label study, adalimumab alone or in combination with standard DMARDs appeared to be well tolerated and effective in 6610 difficult- to- treat patients with active RA treated in clinical practice. [less ▲]

Detailed reference viewed: 90 (2 ULiège)
Full Text
Peer Reviewed
See detailImproved blood pressure control but similar efficacy with lumiracoxib 100 mg OD compared to ibuprofen 600 mg TID in hypertensive patients with osteoarthritis: randomised controlled trial
MacDonald, T.; Littlejohn, T.; Richard, D. et al

in Annals of the Rheumatic Diseases (2007, June), 66(Suppl.II), 502

Detailed reference viewed: 27 (4 ULiège)
Full Text
Peer Reviewed
See detailLong term efficacy of strontium ranelate in reducing the risk of vertebral and non-vertebral including hip fractures in post menopausal osteoporotic women over 5 years
Reginster, Jean-Yves ULiege; Brixen, Kim; Cormier, C. et al

in Annals of the Rheumatic Diseases (2007, June), 66(Suppl.II), 102

Detailed reference viewed: 9 (3 ULiège)
Full Text
Peer Reviewed
See detailA prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip
Luyten, F. P.; Geusens, P.; Malaise, Michel ULiege et al

in Annals of the Rheumatic Diseases (2007), 66(1), 99-106

Objective: To compare the effects of continuous and intermittent celecoxib treatment in patients with knee or hip osteoarthritis in flare. Methods: In this 24-week, prospective, randomised, double-blind ... [more ▼]

Objective: To compare the effects of continuous and intermittent celecoxib treatment in patients with knee or hip osteoarthritis in flare. Methods: In this 24-week, prospective, randomised, double-blind, placebo-controlled study, patients were randomly assigned to receive continuous (n = 62) or intermittent (n = 61) treatment with celecoxib 200 mg once daily. The primary efficacy end point was the area under the curve (AUC) of the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total scores between baseline and week 24 divided by the time interval. Secondary end points included the percentage of days with intake of the flare drug, the AUC of the change in the WOMAC total scores, the mean change from baseline in the WOMAC scores, and the patient's and physician's global assessment of osteoarthritis. Results: There were no significant differences between patients randomised to continuous or intermittent treatment in the primary end point or most of the secondary end points, although a consistent trend supporting continuous treatment was observed. The percentage of days with intake of the flare drug was significantly lower (p = 0.031) in the group receiving continuous versus intermittent celecoxib. Both treatment regimens were well tolerated. Conclusion: The results of this pilot study indicate a potential clinical difference between continuous and intermittent treatment with celecoxib, and may be useful in designing future trials. A larger trial on both efficacy and safety outcomes is required for conclusive evidence in favour of either continuous or intermittent treatment. [less ▲]

Detailed reference viewed: 30 (3 ULiège)
Peer Reviewed
See detailUse of magnetic resonance imaging and 31p-spectroscopy to explore muscle energetics in fibromyalgia patients
Maquet, Didier ULiege; Vanderthommen, Marc ULiege; Lecart, Marie-Paule ULiege et al

in Annals of the Rheumatic Diseases (2007), 66

Background: Fibromyalgia (FM) is defined as a chronic syndrome characterized by diffuse pain. FM patients generally complain of muscle fatigue during physical activities and symptoms worsening after ... [more ▼]

Background: Fibromyalgia (FM) is defined as a chronic syndrome characterized by diffuse pain. FM patients generally complain of muscle fatigue during physical activities and symptoms worsening after exercise. Some studies have explored muscle performances in FM patients. Similarly, we reported that all variables of muscle performances were decreased in FM patients as compared to the controls [1]. We found that muscle impairment predominated over aerobic processes. The 31P nuclear magnetic resonance spectroscopy (NMRS) appears especially useful to study muscle energy metabolism because it is non-invasive and allows the exploration during exercise. Objectives: The purposes were: (1) to determine the maximal transverse section (MTS) of calf muscles by Magnetic Resonance Imaging (MRI) in order to calculate the individual mechanical loads of exercise without requiring the measurement of the maximal voluntary torque; (2) to monitor, by 31P-NMRS, high-energy phosphate metabolism and intracellular pH at rest, during exercise and recovery periods by means of continuous spectra acquisitions with an adequate temporal resolution; (3) to determine an original efficacy muscular index with the help of the ergometric and spectroscopic parameters; (4) to explore the oxidative pathway by means of determination of the PCr rephosphorylation time constant. Methods: Eight women with fibromyalgia (FM) and 30 healthy volunteers were included in this study. MRI of the dominant leg was acquired in order to determine the MTS of calf muscles and thus to calculate the different loads of exercise (dynamic plantar flexions). Subjects performed 3-6 bouts of 2 minutes with workload increments until exhaustion. Spectra were acquired continuously at rest, during the exercise and recovery periods. The analysis concerned the gamma-, alpha- and beta- ATP, Pi, PCr peaks, and intracellular pH. At the end of the exercise, the muscular efficacy index and the PCr re-phosphorylation time constant were calculated. Results: The MTS of the ankle plantar flexors reached respectively 43 cm² and 36.7 cm² in the control and FM groups (p > 0.05). No significant difference (p > 0.05) was observed between both groups in spectroscopic data registered at rest [10.7 (control) vs 9.1 (FM) for PCr/Pi rest ; 7.01 (control) vs 6.99 (FM) for pHrest] and at the end of exercise [1.18 (control) vs 0.68 (FM) for PCr/Pi end ; 6.89 (control) vs 6.81 (FM) for pHend]. However, the muscular efficacy index was significantly reduced in FM patients (1.25) in comparison with control group (2.46) (p < 0.05). Two patients presented an index extremely low (0.3 and 0.4). The PCr time constant was not different between control subjects (27.7 s) and FM patients (25.6 s) (p > 0.05). Conclusion: Our original protocol, not based on maximum voluntary contraction assessment, did not indicate any abnormalities in glycolytic and oxydative pathways in FM patients. We demonstrated a low efficiency of chemical to mechanical energy shift in FM patients. These results suggested a deconditioning syndrome without primitive muscular abnormalities in FM patients and displayed the importance of aerobic muscular rehabilitation. References: [1]Maquet D, Croisier JL, Renard C, Crielaard JM. Muscle performance in patients with fibromyalgia. J Bone Spine. 2002;69:293-9. [less ▲]

Detailed reference viewed: 165 (4 ULiège)
Peer Reviewed
See detailInfluence of specific rehabilitation programs on pressure pain thresholds in patients with fibromyalgia or chronic low back pain
Maquet, Didier ULiege; Demoulin, Christophe ULiege; Lecart, Marie-Paule ULiege et al

in Annals of the Rheumatic Diseases (2007), 66

Background: Specific rehabilitation programs are recommended in chronic pain syndromes. The subjective experience and multidimensional nature of pain is problematic for assessment. Pressure pain threshold ... [more ▼]

Background: Specific rehabilitation programs are recommended in chronic pain syndromes. The subjective experience and multidimensional nature of pain is problematic for assessment. Pressure pain threshold (PPT) is defined as the minimum force applied which induces pain measured with a dolorimeter. Objectives: The purposes were: (1) to compare PPTs for 18 specific tender sites in patients with fibromyalgia (FM) and in patients with chronic low back pain (CLBP), (2) to assess the PPT changes in these groups following specific rehabilitation programs. Methods: Eleven women with CLBP and six women with FM were included in this study. They attended biweekly specific multidisciplinary rehabilitation sessions for 8 weeks. Pain intensity and PPTs for the 18 specific tender sites defined by the American College of Rheumatology were evaluated respectively with a visual analogue scale (VAS) and with an electronic dolorimeter, before and after the programs. Normative data of PPTs were established in a recent study [1]. Results: Before starting the rehabilitation program, patients with FM displayed VAS scores higher (p<0.05) than those with CLBP. Furthermore, FM patients had the lowest (p<0.05) PPTs over all examined areas. Statistical analysis failed to show any differences between PPTs of CLBP and healthy subjects. At the end of the specific program, VAS scores decreased significantly in both patient groups. In contrast, a significant increase of PPTs was only observed in FM patients. However, their PPTs remained below the CLBP and healthy PPT values. Conclusion: Despite the presence of chronic pain in these two syndromes, the decrease of PPTs appears to be specific in patients with FM. Measure of PPTs could represent a relevant method in order to perform a longitudinal follow-up of patient's pain perception. After the rehabilitation programs, pain intensity decreased in both patient groups. References: [1] Maquet D, Croisier JL, Demoulin C, Crielaard JM. Pressure pain thresholds of tender point sites in patients with fibromyalgia and in healthy controls. Eur J Pain, 2004, 8:111-117. [less ▲]

Detailed reference viewed: 77 (7 ULiège)
Full Text
Peer Reviewed
See detailA long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs
Klareskog, L.; Gaubitz, M.; Rodriguez-Valverde, V. et al

in Annals of the Rheumatic Diseases (2006), 65(12), 1578-1584

Objective: To evaluate the long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. Methods: 549 patients entered this 5-year, open-label extension study and received etanercept ... [more ▼]

Objective: To evaluate the long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. Methods: 549 patients entered this 5-year, open-label extension study and received etanercept 25 mg twice weekly. All patients showed inadequate responses to disease-modifying antirheumatic drugs before entry into the double-blind studies. Safety assessments were carried out at regular intervals. Primary efficacy end points were the numbers of painful and swollen joints; secondary variables included American College of Rheumatology (ACR) response rate, Disease Activity Score and acute-phase reactants. Efficacy was analysed using the last-observation-carried-forward approach. Results: Of the 549 patients enrolled in the open-label trial, 467 (85%), 414 (75%) and 371 (68%) completed 1, 2 and 3 years, respectively; 363 (66%) remained in the study at the time of this analysis. A total exposure of 1498 patient-years, including the double-blind study, was accrued. In the open-label trial, withdrawals for efficacy-related and safety-related reasons were 11% and 13%, respectively. Frequent adverse events included upper respiratory infections, flu syndrome, rash and injection-site reactions. Rates of serious infections and malignancies remained unchanged over the course of the study; there were no reports of patients with central demyelinating disease or serious blood dyscrasias. After 3 years, ACR20, ACR50 and ACR70 response rates were 78%, 51% and 27%, respectively. The Disease Activity Score score was reduced to 3.0 at 3 months and 2.6 at 3 years from 5.1. A sustained improvement was found in Health Assessment Questionnaire scores throughout the 3-year time period. Conclusion: After 3 years of treatment, etanercept showed sustained efficacy and a favourable safety profile. [less ▲]

Detailed reference viewed: 38 (1 ULiège)
Full Text
Peer Reviewed
See detailOsteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study
Bruyère, Olivier ULiege; Collette, Julien ULiege; Kothari, M. et al

in Annals of the Rheumatic Diseases (2006), 65(8), 1050-1054

Objective: To investigate the relation between biochemical markers of bone, cartilage, and synovial remodelling and the structural progression of knee osteoarthritis. Methods: 62 patients of both sexes ... [more ▼]

Objective: To investigate the relation between biochemical markers of bone, cartilage, and synovial remodelling and the structural progression of knee osteoarthritis. Methods: 62 patients of both sexes with knee osteoarthritis were followed prospectively for one year. From magnetic resonance imaging ( MRI), done at baseline and after one year, the volume and thickness of cartilage of the femur, the medial tibia, and the lateral tibia were assessed. A whole organ magnetic resonance imaging score ( WORMS) of the knee was calculated for each patient at baseline and at the one year visits. This score consists in a validated, semiquantitative scoring system for whole organ assessment of the knee in osteoarthritis using MRI. Biochemical markers ( serum hyaluronic acid, osteocalcin, cartilage glycoprotein 39 ( YKL-40), cartilage oligomeric matrix protein ( COMP), and C-telopeptide of type I collagen ( CTX-I), and urine C-telopeptide of type II collagen ( CTX-II)) were measured at baseline and after three months. Results: Baseline markers were not correlated with one year changes observed in cartilage volume and thickness. However, an increase in CTX-II after three months was significantly correlated with a one year decrease in mean thickness of medial tibial and lateral tibial cartilage. Patients in the highest quartile of three month changes in CTX-II experienced a mean loss of 0.07 ( 0.08) mm of their medial thickness, compared with a mean increase of 0.05 ( 0.19) mm for patients in the lowest quartile ( p = 0.04) Multiple regression analysis showed that high baseline levels of hyaluronic acid are predictive of a worsening in WORMS ( p = 0.004). Conclusions: These results suggest that a single measurement of serum hyaluronic acid or short term changes in urine CTX-II could identify patients at greatest risk of progression of osteoarthritis. [less ▲]

Detailed reference viewed: 45 (6 ULiège)
Full Text
Peer Reviewed
See detailInfluence of baseline patient characteristics on response to one-monthly and daily oral ibandronate therapy: 2-year findings from MOBILE
Reginster, Jean-Yves ULiege; Hawker, G.; Bolognese, M. et al

in Annals of the Rheumatic Diseases (2006, June), 65(Suppl.II), 426

Detailed reference viewed: 10 (3 ULiège)
Full Text
Peer Reviewed
See detailUpper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate: mobile 2-year analysis
Czerwinski, E.; Nuti, R.; Greenwald, M. et al

in Annals of the Rheumatic Diseases (2006, June), 65(Suppl.II), 415

Detailed reference viewed: 19 (5 ULiège)
Full Text
Peer Reviewed
See detailEfficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
Reginster, Jean-Yves ULiege; Adami, S.; Lakatos, P. et al

in Annals of the Rheumatic Diseases (2006), 65(5), 654-661

BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral ibandronate has been ... [more ▼]

BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral ibandronate has been developed to overcome this problem. OBJECTIVE: To confirm the 1 year results and provide more extensive safety and tolerability information for once-monthly dosing by a 2 year analysis. METHODS: MOBILE, a randomised, phase III, non-inferiority study, compared the efficacy and safety of once-monthly ibandronate with daily ibandronate, which has previously been shown to reduce vertebral fracture risk in comparison with placebo. RESULTS: 1609 postmenopausal women were randomised. Substantial increases in lumbar spine bone mineral density (BMD) were seen in all treatment arms: 5.0%, 5.3%, 5.6%, and 6.6% in the daily and once-monthly groups (50 + 50 mg, 100 mg, and 150 mg), respectively. It was confirmed that all once-monthly regimens were at least as effective as daily treatment, and in addition, 150 mg was found to be better (p<0.001). Substantial increases in proximal femur (total hip, femoral neck, trochanter) BMD were seen; 150 mg produced the most pronounced effect (p<0.05 versus daily treatment). Independent of the regimen, most participants (70.5-93.5%) achieved increases above baseline in lumbar spine or total hip BMD, or both. Pronounced decreases in the biochemical marker of bone resorption, sCTX, observed in all arms after 3 months, were maintained throughout. The 150 mg regimen consistently produced greater increases in BMD and sCTX suppression than the 100 mg and daily regimens. Ibandronate was well tolerated, with a similar incidence of adverse events across groups. CONCLUSIONS: Once-monthly oral ibandronate is at least as effective and well tolerated as daily treatment. Once-monthly administration may be more convenient for patients and improve therapeutic adherence, thereby optimising outcomes. [less ▲]

Detailed reference viewed: 30 (4 ULiège)
Full Text
Peer Reviewed
See detailBone-derived mediators and cartilage degradation
Henrotin, Yves ULiege

in Annals of the Rheumatic Diseases (2006), 65(Suppl II), 10

Detailed reference viewed: 20 (2 ULiège)
Full Text
Peer Reviewed
See detailThree year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study
Bruyère, Olivier ULiege; Richy, F.; Reginster, Jean-Yves ULiege

in Annals of the Rheumatic Diseases (2005), 64(12), 1727-1730

OBJECTIVE: To assess the clinical relevance of mean and minimum femorotibial joint space narrowing (JSN) for predicting future osteoarthritis related surgery in patients with knee osteoarthritis. METHODS ... [more ▼]

OBJECTIVE: To assess the clinical relevance of mean and minimum femorotibial joint space narrowing (JSN) for predicting future osteoarthritis related surgery in patients with knee osteoarthritis. METHODS: 126 subjects with primary knee osteoarthritis were followed prospectively for a mean eight years. Minimum and mean joint space width (JSW) were assessed from standard x rays at baseline and after a follow up of three years. The rate of knee osteoarthritis related surgery was recorded for the following five years. RESULTS: After a mean follow up of eight years, 16 patients (12.7%) had received osteoarthritis related joint surgery. The areas under the curves (AUC) resulting from the receiver operating characteristic curve analyses for predicting osteoarthritis surgery were 0.73 (p=0.006) for minimum JSN and 0.55 (p=0.54) for mean JSN. The cut off for minimum JSN maximising sensitivity and specificity for predicting future surgery was a change of 0.7 mm or more in minimum joint space width over a period of three years. However, no meaningful differences were observed for cut off values between 0.5 and 0.8 mm The relative risk (adjusted for age, body mass index, baseline symptoms, and baseline JSW) of experiencing osteoarthritis related surgery during the eight year of follow up was 5.15 (95% confidence interval, 1.70 to 15.60) (p=0.004) in patients with a minimum joint space narrowing of 0.7 mm or more during the first three years of the study. CONCLUSIONS: A cut off of 0.5 to 0.8 mm in minimum JSN, measured on standard x rays, reflects a clinically relevant progression in patients with knee osteoarthritis. [less ▲]

Detailed reference viewed: 43 (9 ULiège)
Full Text
Peer Reviewed
See detailEULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: Prevalence of inflammation in osteoarthritis
D'Agostino, M. A.; Conaghan, P.; Le Bars, M. et al

in Annals of the Rheumatic Diseases (2005), 64(12), 1703-1709

Objectives: To assess the prevalence of inflammation in subjects with chronic painful knee osteoarthritis (OA), as determined by the presence of synovitis or joint effusion at ultrasonography (US); and to ... [more ▼]

Objectives: To assess the prevalence of inflammation in subjects with chronic painful knee osteoarthritis (OA), as determined by the presence of synovitis or joint effusion at ultrasonography (US); and to evaluate the correlation between synovitis, effusion, and clinical parameters. Methods: A cross sectional, multicentre, European study was conducted under the umbrella of EULAR-ESCISIT. Subjects had primary chronic knee OA (ACR criteria) with pain during physical activity >= 30 mm for at least 48 hours. Clinical parameters were collected by a rheumatologist and an US examination of the painful knee was performed by a radiologist or rheumatologist within 72 hours of the clinical examination. Ultrasonographic synovitis was defined as synovial thickness >= 4 mm and diffuse or nodular appearance, and a joint effusion was defined as effusion depth >= 4 mm. Results: 600 patients with painful knee OA were analysed. At US 16 (2.7%) had synovitis alone, 85 (14.2%) had both synovitis and effusion, 177 (29.5%) had joint effusion alone, and 322 (53.7%) had no inflammation according to the definitions employed. Multivariate analysis showed that inflammation seen by US correlated statistically with advanced radiographic disease (Kellgren-Lawrence grade >= 3; odds ratio (OR) = 2.20 and 1.91 for synovitis and joint effusion, respectively), and with clinical signs and symptoms suggestive of an inflammatory "flare'', such as joint effusion on clinical examination (OR = 1.97 and 2.70 for synovitis and joint effusion, respectively) or sudden aggravation of knee pain (OR = 1.77 for joint effusion). Conclusion: US can detect synovial inflammation and effusion in painful knee OA, which correlate significantly with knee synovitis, effusion, and clinical parameters suggestive of an inflammatory "flare''. [less ▲]

Detailed reference viewed: 29 (0 ULiège)
Full Text
Peer Reviewed
See detailGlobal prevalence and skeletal implications of vitamin D inadequacy
Reginster, Jean-Yves ULiege; Richy, Florent; Rabenda, Véronique ULiege et al

in Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 362

Detailed reference viewed: 18 (4 ULiège)
Full Text
Peer Reviewed
See detailIntravenous ibandronate injections are at least as effective as daily oral ibandronate: consistent effect across subgroups
Reginster, Jean-Yves ULiege; Stepan, J. J.; Halse, J. et al

in Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 365

Detailed reference viewed: 10 (1 ULiège)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women whatever the baseline vertebral fractures status
Roux, Christian; Fardellone, P.; Fechtenbaum, Jacques et al

in Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 359

Detailed reference viewed: 11 (6 ULiège)
Full Text
Peer Reviewed
See detailReduction in the risk of back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis
Reginster, Jean-Yves ULiege; Nevitt, M. C.; Chen, P. et al

in Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 521

Detailed reference viewed: 4 (1 ULiège)
Full Text
Peer Reviewed
See detailOnce-monthly and daily oral ibandronate are at least as effective in improving proximal femur BMD in postmenopausal osteoporosis: 12-month data from MOBILE
Reginster, Jean-Yves ULiege; Lorenc, R.; Stepan, J. J. et al

in Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 93

Detailed reference viewed: 3 (1 ULiège)
Full Text
Peer Reviewed
See detailTwo-year efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: the MOBILE study
Cooper, C.; Delmas, P. D.; Felsenberg, D. et al

in Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 68

Detailed reference viewed: 22 (5 ULiège)